Literature DB >> 2155971

From the National Institute of Allergy and Infectious Diseases and the World Health Organization. Respiratory syncytial and parainfluenza viruses.

C A Heilman1.   

Abstract

Entities:  

Mesh：

Year:  1990        PMID： 2155971     DOI： 10.1093/infdis/161.3.402

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  56 in total

1.  Respiratory syncytial virus immunoprophylaxis: impact on epidemiology.

Authors:  N N Dougherty; H C Meissner
Journal:  Paediatr Drugs       Date:  2000 Mar-Apr       Impact factor: 3.022

2.  Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease.

Authors:  H C Meissner; J R Groothuis; W J Rodriguez; R C Welliver; G Hogg; P H Gray; R Loh; E A Simoes; P Sly; A K Miller; A I Nichols; D K Jorkasky; D E Everitt; K A Thompson
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Central role of dendritic cells in shaping the adaptive immune response during respiratory syncytial virus infection.

Authors:  Daniel S McDermott; Kayla A Weiss; Cory J Knudson; Steven M Varga
Journal:  Future Virol       Date:  2011-08       Impact factor: 1.831

4.  Analysis of the primary T-cell response to Sendai virus infection in C57BL/6 mice: CD4+ T-cell recognition is directed predominantly to the hemagglutinin-neuraminidase glycoprotein.

Authors:  G A Cole; J M Katz; T L Hogg; K W Ryan; A Portner; D L Woodland
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

Review 5.  Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients.

Authors:  S Samuel Weigt; Aric L Gregson; Jane C Deng; Joseph P Lynch; John A Belperio
Journal:  Semin Respir Crit Care Med       Date:  2011-08-19       Impact factor: 3.119

6.  Fas ligand is required for the development of respiratory syncytial virus vaccine-enhanced disease.

Authors:  Matthew R Olson; Steven M Varga
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

7.  The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses.

Authors:  K F Hu; M Elvander; M Merza; L Akerblom; A Brandenburg; B Morein
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

8.  Respiratory syncytial virus induces interleukin-10 by human alveolar macrophages. Suppression of early cytokine production and implications for incomplete immunity.

Authors:  J R Panuska; R Merolla; N A Rebert; S P Hoffmann; P Tsivitse; N M Cirino; R H Silverman; J A Rankin
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

9.  Cutting edge: Eosinophils do not contribute to respiratory syncytial virus vaccine-enhanced disease.

Authors:  Elaine M Castilow; Kevin L Legge; Steven M Varga
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

10.  Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.

Authors:  Bart Jones; Xiaoyan Zhan; Vasiliy Mishin; Karen S Slobod; Sherri Surman; Charles J Russell; Allen Portner; Julia L Hurwitz
Journal:  Vaccine       Date:  2009-02-04       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.